Hepatitis/MASH

Cannabidiol found in cannabis could be used as a novel treatment for hepatitis C virus

Cannabidiol was overserved to elicit antiviral properties against HCV.

The Iowa Department of Public Health released its first report on hepatitis C virus.

Flawed patents challenged on blockbuster HCV drugs to allow generic production.

Assay quantitates HCV viral load and confirms active HCV infection.

Research indicates hepatitis C virus is linked to cancers other than hepatocellular carcinoma and non-Hodgkin lymphoma.

New findings suggest that hepatitis C may cause cancers other than hepatocellular carcinoma and non-Hodgkin lymphoma.

Top articles of the week on Specialty Pharmacy Times.

Glecaprevir/pribrentasvir well-tolerated in patients with HCV genotype 1.

For patients with HIV, liver disease is a major cause of morbidity and mortality.

Proposals such as allowing Medicare price negotiation, capping out-of-pocket drug costs, importing drugs, and limiting manufacturer’ spending on patient marketing could all result in lower HCV drug costs.

The prevalence of cirrhosis has increased by nearly 40% in patients with HCV.

With the entrance of more effective and less costly drugs, older treatments will likely decrease.

HCV rates 3 times higher in patients with lupus.

The FDA has accepted AbbVie’s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P).

Top articles of the week from Specialty Pharmacy Times.

Fake hepatitis C pills are entering the distribution network through back-channel wholesalers.

RG-101 placed on clinical hold last year after a second reported case of jaundice.

Regulus Therapeutics treatment reduces HCV replication in the liver.

New index more precisely determines the probability of reducing liver fat during lifestyle interventions.

A recently-published Institute for Safe Medication Practices (ISMP) report details updated concerns about newer drugs used to treat hepatitis C virus (HCV).

The new test service helps physicians assess patient’s responses to antiretroviral therapy for HBV.

Simeprevir was approved by the FDA in late 2013 for hepatitis C virus.

Severe adverse events may be associated with new class of hepatitis C medications.

Sofosbuvir/velpatasvir/voxilaprevir granted accelerated assessment for the treatment of hepatitis C.